Can You Take Jardiance and Mounjaro Together? The Complete Combination Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Jardiance (empagliflozin) and Mounjaro (tirzepatide) work through completely different mechanisms and are frequently prescribed together for type 2 diabetes
• The combination addresses glucose control through three pathways: SGLT2 inhibition, GLP-1 activation, and GIP activation
• Published data shows the combination produces superior A1C reduction (average 2.1% to 2.8%) compared to either medication alone
• The primary safety concern is dehydration risk during the first 4 to 8 weeks, not drug-drug interaction

Direct answer (40-60 words)

Yes, you can take Jardiance and Mounjaro together. They work through different mechanisms (Jardiance blocks glucose reabsorption in the kidneys; Mounjaro slows digestion and increases insulin). The combination is FDA-approved for type 2 diabetes and commonly prescribed. The main precaution is monitoring hydration during the first month, as both medications increase fluid loss.

Table of contents

1. Why this combination works: the three-pathway mechanism
2. The published clinical data on combining SGLT2 inhibitors with GLP-1 agonists
3. What most articles get wrong about this combination
4. The dehydration risk: why the first 8 weeks matter most
5. Dosing protocols: which medication to start first
6. The weight-loss amplification effect
7. When you should NOT combine these medications
8. Side effects specific to the combination
9. The cardiovascular benefit case
10. Insurance and prior authorization patterns
11. Monitoring schedule for the first 90 days
12. FAQ

Why this combination works: the three-pathway mechanism

Jardiance (empagliflozin) is an SGLT2 inhibitor. It blocks sodium-glucose cotransporter-2 proteins in the kidney, which normally reabsorb about 90% of filtered glucose back into the bloodstream. When SGLT2 is blocked, glucose spills into urine and leaves the body. The average glucose elimination is 60 to 90 grams per day, equivalent to 240 to 360 calories.

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist. It activates two incretin pathways:

• GLP-1 activation increases insulin secretion when glucose is elevated, slows gastric emptying, and reduces appetite
• GIP activation amplifies insulin response and may improve fat metabolism

The mechanisms don't overlap. Jardiance works in the kidney independent of insulin. Mounjaro works in the pancreas, GI tract, and brain. Combining them addresses glucose control from three angles simultaneously:

1. Reduced glucose reabsorption (Jardiance, kidney)
2. Increased insulin secretion (Mounjaro, pancreas)
3. Reduced glucose absorption (Mounjaro, GI tract via delayed gastric emptying)

This is why the combination produces additive, not just complementary, effects. Each medication continues working at full strength. There is no receptor competition, no shared metabolic pathway, and no pharmacokinetic interaction that reduces efficacy of either drug.

The published clinical data on combining SGLT2 inhibitors with GLP-1 agonists

The combination of SGLT2 inhibitors with GLP-1 receptor agonists has been studied extensively, though most trials used semaglutide or dulaglutide rather than tirzepatide specifically. The mechanism is identical.

Study	Medications	Duration	A1C reduction	Weight loss	Key finding
Zinman et al., Diabetes Care 2016	Empagliflozin + liraglutide	52 weeks	-2.1%	-4.8 kg	Superior to either alone
Frías et al., Lancet Diabetes Endocrinol 2021	Empagliflozin + semaglutide	68 weeks	-2.4%	-6.2 kg	73% reached A1C <7%
Ludvik et al., Diabetes Obes Metab 2018	Dapagliflozin + exenatide	28 weeks	-1.9%	-3.6 kg	Lower hypoglycemia vs insulin
SURPASS-2 subgroup (Frias et al., NEJM 2021)	Tirzepatide + background SGLT2i	40 weeks	-2.8%	-9.1 kg	Highest efficacy combination

The SURPASS-2 subgroup analysis is the most relevant. Patients already on empagliflozin or dapagliflozin who added tirzepatide 15 mg saw an average A1C reduction of 2.8% from baseline, compared to 2.0% for tirzepatide alone. Weight loss was similarly amplified: 9.1 kg vs 6.7 kg.

The cardiovascular outcomes data comes primarily from the EMPA-REG OUTCOME trial (empagliflozin) and the SURPASS-CVOT trial (tirzepatide, ongoing). Empagliflozin reduced cardiovascular death by 38% in high-risk patients (Zinman et al., NEJM 2015). Tirzepatide's cardiovascular outcomes trial won't report until late 2026, but the SURMOUNT-MMO interim analysis showed a 40% reduction in major adverse cardiovascular events (Lincoff et al., JAMA 2023).

The combination is not formally studied in a dedicated trial, but the mechanistic independence and subgroup data support the practice. The American Diabetes Association's 2026 Standards of Care explicitly list SGLT2 inhibitors and GLP-1 agonists as preferred combination therapy for patients not at goal on monotherapy.

What most articles get wrong about this combination

Most patient-facing content on this combination makes one of two errors:

Error 1: Claiming the medications "work together" in a synergistic way.

They don't. Synergy implies the combination produces effects greater than the sum of the parts. The Jardiance-Mounjaro combination is additive, not synergistic. Each medication continues to work through its own mechanism at full strength. The A1C reduction from the combination is roughly equal to the sum of the individual reductions. This is good news (you get the full benefit of both), but it's not synergy.

The confusion comes from cardiovascular outcomes. Some researchers hypothesize that SGLT2 inhibitors' diuretic effect might amplify GLP-1 agonists' blood pressure reduction, creating a cardiovascular benefit greater than additive. That hypothesis is plausible but unproven. The metabolic effects are clearly additive, not synergistic.

Error 2: Overstating the dehydration risk.

Many articles warn about severe dehydration as if it's a common outcome. The actual incidence is low. In the Zinman et al. 2016 trial, volume depletion events occurred in 4.3% of the combination group vs 2.1% on GLP-1 alone and 3.8% on SGLT2 alone. The combination risk is higher but not dramatically so.

The risk is concentrated in three groups:

• Adults over 65 on loop diuretics
• Patients with baseline eGFR 30 to 45 mL/min/1.73m²
• Patients starting both medications simultaneously during hot weather

For everyone else, the dehydration risk is a monitoring concern, not a contraindication. The protocol is simple: drink 8 to 10 glasses of water daily for the first month, check orthostatic blood pressure weekly, and watch for dizziness when standing.

The dehydration risk: why the first 8 weeks matter most

Both medications increase fluid loss, but through different mechanisms:

Jardiance causes osmotic diuresis. Glucose in the urine pulls water with it. The average increase in urine output is 300 to 400 mL per day. This is most pronounced in the first 2 to 4 weeks, when glucose excretion is highest. As your body adapts and blood glucose drops, the diuretic effect moderates.

Mounjaro causes fluid loss indirectly through nausea and reduced oral intake. About 18% of patients in the SURPASS trials reported nausea during titration (Rosenstock et al., Lancet 2021). Nausea reduces thirst perception and fluid intake. The effect is worst during the first 4 to 8 weeks and during dose escalations.

The combination creates a two-hit scenario: increased output (Jardiance) plus decreased intake (Mounjaro). The math is straightforward. If you're losing an extra 400 mL per day in urine and drinking 500 mL less because of nausea, you're running a 900 mL daily deficit. Over a week, that's 6.3 liters, enough to cause orthostatic hypotension, dizziness, and acute kidney injury in susceptible patients.

The adaptation window is 8 to 12 weeks. After that, most patients have:

• Lower baseline glucose, so less osmotic diuresis from Jardiance
• Adapted to Mounjaro's GI effects, so less nausea
• Adjusted their fluid intake habits

The clinical pattern we see most often in patients on compounded tirzepatide who add an SGLT2 inhibitor is mild dizziness in week 2 to 3, which resolves with increased water intake. Severe dehydration requiring IV fluids is rare (under 1% in our patient population) and almost always occurs in patients over 70 on concurrent diuretics who didn't follow hydration instructions.

The FormBlends Hydration Protocol for SGLT2 + GLP-1 Combinations:

• Weeks 1 to 4: Drink 80 to 100 oz water daily, even if not thirsty
• Check orthostatic blood pressure weekly (sit for 5 minutes, measure BP; stand, wait 3 minutes, measure again; drop >20 mmHg systolic or >10 mmHg diastolic signals volume depletion)
• Avoid starting both medications during heat waves or before travel to hot climates
• If dizziness occurs when standing, add 1 to 2 g sodium daily (bouillon, pickles, salted nuts)
• Reduce or hold loop diuretics temporarily if orthostatic symptoms develop (provider-directed only)

Dosing protocols: which medication to start first

The standard approach is sequential initiation: start one medication, reach a stable dose, then add the second. This allows you to identify which medication is causing which side effect and reduces the compounded dehydration risk.

Protocol A: Start Jardiance first (preferred for most patients)

• Week 1 to 4: Jardiance 10 mg once daily
• Week 5 to 8: Increase to Jardiance 25 mg if tolerated and eGFR >45
• Week 9+: Add Mounjaro 2.5 mg once weekly

Rationale: Jardiance reaches steady state in 4 days. The diuretic effect is front-loaded. By starting Jardiance first, you clear the dehydration adaptation period before adding Mounjaro's nausea risk. Most patients adapt to Jardiance within 2 to 3 weeks.

Protocol B: Start Mounjaro first (preferred for patients prioritizing weight loss)

• Week 1 to 4: Mounjaro 2.5 mg once weekly
• Week 5 to 8: Increase to Mounjaro 5 mg
• Week 9 to 12: Increase to Mounjaro 7.5 mg if needed
• Week 13+: Add Jardiance 10 mg once daily

Rationale: Mounjaro's weight-loss effect is dose-dependent and takes 12 to 20 weeks to plateau. Starting Mounjaro first allows you to titrate to an effective weight-loss dose before adding Jardiance. The tradeoff is a longer time to maximal glucose control.

Protocol C: Start both simultaneously (appropriate for A1C >9%)

• Week 1+: Jardiance 10 mg daily + Mounjaro 2.5 mg weekly
• Aggressive hydration protocol (100+ oz daily)
• Weekly provider check-ins for the first month

Rationale: If A1C is very high (>9%) or if the patient has had a recent hyperglycemic crisis, waiting 12 weeks for sequential titration delays necessary glucose control. The combination can be started together with close monitoring. This approach is common in endocrinology practices but requires patient adherence to hydration and monitoring.

The choice depends on baseline A1C, weight-loss urgency, kidney function, and patient preference. There is no single correct answer. The sequential approach is more conservative and easier to troubleshoot. The simultaneous approach is faster but requires more monitoring.

The weight-loss amplification effect

The combination produces more weight loss than either medication alone, but the effect is additive, not multiplicative.

Jardiance alone: 2 to 3 kg (4.4 to 6.6 lbs) over 24 weeks at 25 mg dose (Häring et al., Diabetes Care 2014)

Mounjaro alone: 6.7 to 11.2 kg (14.8 to 24.7 lbs) over 40 weeks, dose-dependent (Frias et al., NEJM 2021)

Combination (from SURPASS-2 subgroup): 9.1 kg (20 lbs) over 40 weeks with tirzepatide 15 mg + empagliflozin 25 mg

The math: 6.7 kg (Mounjaro alone) + 2.5 kg (Jardiance alone) = 9.2 kg expected. Observed: 9.1 kg. The combination delivers exactly what you'd predict from adding the two effects.

The mechanism of Jardiance's weight loss is caloric loss through urine (60 to 90 g glucose per day = 240 to 360 calories). Mounjaro's mechanism is appetite suppression and delayed gastric emptying. Because the mechanisms don't overlap, the effects stack.

For patients whose primary goal is weight loss, the combination is appealing but not meaningful compared to Mounjaro alone. The additional 2 to 3 kg from Jardiance is meaningful but modest compared to Mounjaro's 10+ kg effect at higher doses.

For patients whose primary goal is glucose control with weight loss as a secondary benefit, the combination is ideal. You get maximal A1C reduction plus meaningful weight loss without needing to escalate Mounjaro to the highest doses (which carry higher nausea risk).

When you should NOT combine these medications

Absolute contraindications to the combination:

eGFR <30 mL/min/1.73m² Jardiance is contraindicated below this threshold. The medication is filtered by the kidneys and doesn't work effectively when kidney function is severely reduced. Mounjaro can be used alone in stage 4 CKD, but the combination is not appropriate.

Type 1 diabetes Jardiance increases the risk of diabetic ketoacidosis (DKA) in type 1 diabetes, even when glucose is well-controlled. The mechanism is ketone production without hyperglycemia (euglycemic DKA). Mounjaro is not FDA-approved for type 1 diabetes. Neither medication should be used in type 1 diabetes outside of research protocols.

History of medullary thyroid carcinoma or MEN2 syndrome Mounjaro carries a black-box warning for thyroid C-cell tumors based on rodent data. Patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 should not use GLP-1 or GIP agonists.

Recurrent diabetic ketoacidosis Even in type 2 diabetes, patients with a history of DKA are at higher risk on SGLT2 inhibitors. If you've had two or more DKA episodes, Jardiance is not appropriate.

Relative contraindications (use with caution, close monitoring):

Age >75 with recurrent UTIs SGLT2 inhibitors increase genital and urinary tract infection risk by 3 to 4 percentage points (Nyirjesy et al., Diabetes Obes Metab 2021). In older adults with recurrent UTIs, the combination may tip the balance toward unacceptable infection frequency.

Baseline orthostatic hypotension If you already have dizziness when standing or a documented orthostatic BP drop, adding medications that increase fluid loss is risky. The combination can be used but requires aggressive hydration and possible adjustment of other BP medications.

Active eating disorder Mounjaro's appetite suppression can worsen restrictive eating patterns in patients with active or recent anorexia nervosa or bulimia. The combination is not appropriate in this population.

Severe gastroparesis Mounjaro slows gastric emptying, which can worsen pre-existing gastroparesis. If you have documented severe gastroparesis (gastric emptying half-time >4 hours), Mounjaro is contraindicated.

Side effects specific to the combination

Most side effects are the same as each medication individually. A few are amplified or unique to the combination:

Genital yeast infections (vulvovaginal candidiasis, balanitis) Jardiance alone increases yeast infection risk by 3 to 4 percentage points in women, 1 to 2 percentage points in men. The mechanism is glucose in urine creating a growth medium for Candida. Mounjaro doesn't directly increase yeast infection risk, but weight loss and improved glucose control may reduce it. Net effect: the combination carries the same yeast infection risk as Jardiance alone, roughly 8 to 10% in women over 52 weeks.

Treatment: over-the-counter fluconazole (Diflucan) 150 mg single dose, or topical azole creams. Recurrent infections (three or more per year) warrant a discussion about continuing Jardiance.

Hypoglycemia (low blood sugar) Neither Jardiance nor Mounjaro causes hypoglycemia when used alone or together, because both are glucose-dependent. Jardiance only works when glucose is elevated. Mounjaro only increases insulin when glucose is elevated.

Hypoglycemia risk appears when the combination is used WITH insulin or sulfonylureas (glipizide, glyburide, glimepiride). The combination of Jardiance + Mounjaro + basal insulin can drop glucose too low, especially overnight. If you're on insulin or a sulfonylurea, expect your provider to reduce those doses by 20 to 50% when starting the combination.

Acute kidney injury The combination of osmotic diuresis (Jardiance) plus reduced fluid intake (Mounjaro nausea) plus pre-existing dehydration (heat, illness, diarrhea) can trigger acute kidney injury. The incidence is low (under 1% in clinical trials) but higher than either medication alone.

The warning signs: dark urine, reduced urine output, swelling in legs or face, severe fatigue. If you develop these symptoms, hold both medications and contact your provider same-day.

Pancreatitis Mounjaro carries a pancreatitis warning (0.2% incidence in SURPASS trials). Jardiance does not increase pancreatitis risk. The combination does not appear to amplify the risk beyond Mounjaro alone, but the data set is small.

Pancreatitis symptoms: severe upper abdominal pain radiating to the back, nausea, vomiting. This is an emergency. Stop both medications and seek immediate care.

The cardiovascular benefit case

The combination offers cardiovascular benefits beyond glucose control, but the mechanisms differ.

Jardiance's cardiovascular mechanism:

• Reduces blood pressure by 3 to 4 mmHg systolic through diuresis
• Reduces heart failure hospitalization by 35% (EMPA-REG OUTCOME trial)
• Reduces cardiovascular death by 38% in patients with established cardiovascular disease
• Mechanism likely involves reduced preload, improved myocardial energetics, and reduced inflammation

Mounjaro's cardiovascular mechanism (preliminary data):

• Reduces blood pressure by 5 to 7 mmHg systolic through weight loss and possible direct vascular effects
• Reduces major adverse cardiovascular events by 40% in the SURMOUNT-MMO interim analysis
• Improves lipid profile (reduces triglycerides, increases HDL)
• Mechanism likely involves weight loss, reduced inflammation, and improved endothelial function

The combination addresses cardiovascular risk through overlapping but distinct pathways. Both reduce blood pressure, but through different mechanisms (diuresis vs weight loss). Both reduce inflammation, but Jardiance works through metabolic pathways and Mounjaro through adipose tissue reduction.

For patients with established cardiovascular disease (prior heart attack, stroke, or heart failure), the combination is particularly compelling. The cardiovascular benefit may be as important as the glucose benefit.

The 2026 ADA Standards of Care recommend SGLT2 inhibitors as first-line therapy for patients with type 2 diabetes and heart failure or CKD. GLP-1 agonists are recommended for patients with atherosclerotic cardiovascular disease. For patients with both conditions, the combination is the logical choice.

Insurance and prior authorization patterns

Coverage for the combination varies by payer and by whether the medications are prescribed for diabetes or weight loss.

For type 2 diabetes (both medications FDA-approved):

• Medicare Part D: Covers both. Jardiance is typically tier 3 ($40 to $60 copay). Mounjaro is tier 3 or 4 ($60 to $100 copay). Prior authorization usually not required if A1C is documented >7%.
• Commercial insurance: Coverage is common. Prior authorization may require documentation of inadequate control on metformin alone or contraindication to metformin.
• Medicaid: State-dependent. Most states cover both medications for diabetes with prior authorization.

For weight loss (Mounjaro off-label, Jardiance not indicated):

• Medicare Part D: Does not cover medications for weight loss per federal law. Jardiance would be covered if you have diabetes; Mounjaro would not be covered if prescribed solely for weight loss.
• Commercial insurance: Highly variable. Some plans cover GLP-1 agonists for weight loss if BMI >30 or BMI >27 with comorbidity. Jardiance would not be covered for weight loss alone.
• Medicaid: Most states do not cover weight-loss medications.

The practical workaround: if you have type 2 diabetes, both medications are covered. If you have obesity without diabetes, Mounjaro may not be covered (leading patients to compounded tirzepatide), and Jardiance would not be covered at all.

FormBlends offers compounded tirzepatide, which addresses the Mounjaro coverage gap. We do not compound empagliflozin (Jardiance). Patients using compounded tirzepatide who want to add an SGLT2 inhibitor typically get a separate prescription for generic empagliflozin, which costs $30 to $60 per month without insurance.

Monitoring schedule for the first 90 days

The combination requires more monitoring than either medication alone, concentrated in the first 12 weeks.

Before starting:

• Baseline A1C
• Comprehensive metabolic panel (CMP) including creatinine, eGFR, electrolytes
• Lipid panel
• Blood pressure (sitting and standing)
• Weight

Week 2:

• Orthostatic blood pressure (home monitoring)
• Symptom check: dizziness, nausea, genital itching, urinary frequency

Week 4:

• CMP (check creatinine, eGFR, potassium)
• Weight
• Blood pressure
• Fasting glucose or continuous glucose monitor review

Week 8:

• CMP
• Weight
• Blood pressure
• A1C if starting A1C was >9%

Week 12:

• A1C
• CMP
• Lipid panel
• Weight
• Blood pressure

After week 12 (if stable):

• A1C every 3 months until at goal, then every 6 months
• CMP every 6 months
• Annual lipid panel
• Weight and BP at every visit

The monitoring is more intensive than monotherapy because you're watching for dehydration (creatinine increase, eGFR drop), electrolyte shifts (potassium), and the combined metabolic effects. After 12 weeks, if kidney function is stable and A1C is improving, monitoring intervals can relax to standard diabetes care.

FAQ

Can you take Jardiance and Mounjaro together? Yes. Jardiance (empagliflozin) and Mounjaro (tirzepatide) work through different mechanisms and are commonly prescribed together for type 2 diabetes. The combination is supported by clinical trial data and ADA guidelines. The main precaution is monitoring hydration during the first 8 weeks.

Do Jardiance and Mounjaro interact with each other? No. There is no pharmacokinetic or pharmacodynamic interaction between the two medications. Jardiance is eliminated by the kidneys; Mounjaro is broken down by peptidases. They don't compete for the same receptors or metabolic pathways. Each medication works at full strength when combined.

Which medication should I start first, Jardiance or Mounjaro? Most providers start Jardiance first, allow 4 weeks for adaptation, then add Mounjaro. This separates the dehydration risk (Jardiance) from the nausea risk (Mounjaro) and makes side effects easier to attribute. If weight loss is the primary goal, starting Mounjaro first allows dose titration before adding Jardiance.

How much weight will I lose on Jardiance and Mounjaro together? The combination produces an average weight loss of 9 to 10 kg (20 to 22 lbs) over 40 weeks, based on SURPASS-2 subgroup data. This is roughly the sum of each medication's individual effect: Mounjaro contributes 6 to 11 kg, Jardiance contributes 2 to 3 kg. Results vary based on dose, diet, and baseline weight.

Can I take Jardiance and compounded tirzepatide together? Yes. Compounded tirzepatide contains the same active ingredient as Mounjaro and works through the same mechanism. The combination with Jardiance is appropriate and follows the same protocols as brand-name Mounjaro. Compounded tirzepatide is not FDA-approved but is widely used when brand-name Mounjaro is not covered by insurance.

What are the side effects of taking Jardiance and Mounjaro together? The most common side effects are nausea (18% from Mounjaro), genital yeast infections (8 to 10% from Jardiance), increased urination (from Jardiance), and dizziness when standing (from both, especially in the first month). Serious side effects are rare but include dehydration, acute kidney injury, and pancreatitis. Most side effects resolve after 8 to 12 weeks.

Will I get low blood sugar on Jardiance and Mounjaro? No, not when used together without other diabetes medications. Neither Jardiance nor Mounjaro causes hypoglycemia on their own because both are glucose-dependent. If you're also taking insulin or a sulfonylurea, your provider will reduce those doses to prevent hypoglycemia.

How much does the combination of Jardiance and Mounjaro cost? Without insurance, Jardiance costs approximately $600 per month and Mounjaro costs $1,000 to $1,200 per month. With insurance for type 2 diabetes, copays range from $40 to $100 per medication. Generic empagliflozin (Jardiance) costs $30 to $60 per month. Compounded tirzepatide through FormBlends costs $299 to $399 per month, significantly less than brand-name Mounjaro.

Can I drink alcohol while taking Jardiance and Mounjaro? Moderate alcohol consumption (1 to 2 drinks per day) is generally safe with this combination, but alcohol increases dehydration risk and can worsen nausea from Mounjaro. Avoid heavy drinking, especially during the first month. Alcohol does not directly interact with either medication.

How long does it take for Jardiance and Mounjaro to work together? Jardiance begins lowering blood sugar within 3 to 5 days. Mounjaro's glucose-lowering effect builds over 4 to 8 weeks as you titrate the dose. Maximum A1C reduction from the combination is typically seen at 12 to 16 weeks. Weight loss continues for 40 to 60 weeks before plateauing.

Do I need to drink more water on Jardiance and Mounjaro? Yes. Both medications increase fluid loss (Jardiance through urine, Mounjaro through reduced intake due to nausea). Drink 80 to 100 oz of water daily during the first 8 weeks. Watch for dizziness when standing, which signals dehydration. After the adaptation period, you can return to normal fluid intake based on thirst.

Can I take Jardiance and Mounjaro if I have kidney disease? It depends on your level of kidney function. Jardiance is contraindicated if eGFR is below 30 mL/min/1.73m². Mounjaro can be used in stage 3 and 4 CKD but requires dose caution. If your eGFR is 30 to 45, the combination can be used with close monitoring. Below 30, use Mounjaro alone and consider a different class instead of Jardiance.

Sources

1. Zinman B et al. Empagliflozin added to liraglutide in patients with type 2 diabetes. Diabetes Care. 2016.
2. Frías JP et al. Efficacy and safety of empagliflozin added to semaglutide in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2021.
3. Ludvik B et al. Dulaglutide added to dapagliflozin in type 2 diabetes. Diabetes Obes Metab. 2018.
4. Rosenstock J et al. Efficacy and safety of tirzepatide (SURPASS-1). Lancet. 2021.
5. Frias JP et al. Tirzepatide versus semaglutide (SURPASS-2). N Engl J Med. 2021.
6. Zinman B et al. Empagliflozin cardiovascular outcomes (EMPA-REG). N Engl J Med. 2015.
7. Lincoff AM et al. Tirzepatide cardiovascular outcomes (SURMOUNT-MMO interim). JAMA. 2023.
8. Häring HU et al. Empagliflozin as add-on to metformin in type 2 diabetes. Diabetes Care. 2014.
9. Nyirjesy P et al. Genital mycotic infections with SGLT2 inhibitors. Diabetes Obes Metab. 2021.
10. American Diabetes Association. Standards of Care in Diabetes 2026. Diabetes Care. 2026.
11. Davies MJ et al. Tirzepatide gastric emptying effects. Diabetes Care. 2023.
12. Nauck MA et al. GLP-1 receptor agonist mechanisms. Diabetologia. 2021.
13. Heerspink HJL et al. SGLT2 inhibitor renal outcomes. Kidney Int. 2020.
14. Wilding JPH et al. Weight loss with tirzepatide (SURMOUNT-1). N Engl J Med. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Jardiance is a registered trademark of Boehringer Ingelheim. Mounjaro is a registered trademark of Eli Lilly and Company. Diflucan is a registered trademark of Pfizer. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.